OliX Pharmaceuticals
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
OliX Pharmaceuticals develops medicines that work by silencing the specific genes responsible for hard-to-treat diseases, a technique known as RNA interference (RNAi).
It focuses on a proprietary molecule structure called cp-asiRNA, which is designed to block disease-causing proteins more precisely and with fewer unwanted side effects than earlier approaches. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company operates primarily as a technology-licensing business, transferring its RNAi platform and drug-candidate rights to domestic and international pharmaceutical companies in exchange for fees.
Summary is AI-generated and may contain errors · figures from DART filings
OliX Pharmaceuticals in five facts
What does OliX Pharmaceuticals do?
OliX Pharmaceuticals develops medicines that work by silencing the specific genes responsible for hard-to-treat diseases, a technique known as RNA interference (RNAi).
Where is OliX Pharmaceuticals listed and in which sector?
OliX Pharmaceuticals (Korean name: 올릭스) trades under KRX code 226950 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is OliX Pharmaceuticals?
Its market capitalisation was US$1.8B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were OliX Pharmaceuticals's latest annual revenue and operating profit?
For fiscal year 2025, OliX Pharmaceuticals reported revenue of US$11.1M, an operating loss of US$22.6M and a net loss of US$11.9M, per its annual report on DART (data retrieved from DART on 2026-09-18). Revenue was up 158.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-18
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meetingOct 14
- Material management matter relevant to investment decisionsOct 12
- [Amended] Material management matter relevant to investment decisionsOct 8
- Investor relations (IR) meetingOct 6
- [Amended] Material management matter relevant to investment decisionsSep 30
- Material management matter relevant to investment decisionsSep 16
- [Amended] Material management matter relevant to investment decisionsSep 8
- DisclosureSep 1
- Report on large shareholdings (5% rule) (abbreviated)Sep 1
- DisclosureAug 31
- [Amended] Material event report (rights offering)
OliX Pharmaceuticals updated the terms of a private placement (third-party allotment) to raise US$7M, about 0.4% of its market value.
Capital raise · Jul 8 · 2 versions - [Amended] Material event report (rights offering)
OliX Pharmaceuticals updated the terms of a private placement (third-party allotment) to raise US$71.8M, about 4.0% of its market value.
Capital raise · Jun 29 · 2 versions - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
OliX Pharmaceuticals reported consolidated results for FY2025: revenue of US$10.2M (+158.3% year on year), an operating loss of US$21.1M and a net loss of US$11.2M.
Earnings · Feb 12